SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: arnie h who wrote (1011)2/20/2000 10:05:00 AM
From: arnie h  Read Replies (1) of 1386
 
Interesting article in this week's Economist. Full-scale clinical trials with cannabis candidates will be starting in the next few weeks on patients in Britain." The purpose of the trials now about to begin is to establish a dose and method of oral application which will allow patients to benefit from the effects of cannabis without smoking and without experiencing a high." Possible beneficiaries are seen as patients with MS, AIDS and those undergoing chemotherapy.
Pars would appear to be the leader in the cannabis area.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News